Literature DB >> 1907149

Glucuronidation of 3'-azido-3'-deoxythymidine catalyzed by human liver UDP-glucuronosyltransferase. Significance of nucleoside hydrophobicity and inhibition by xenobiotics.

A Resetar1, D Minick, T Spector.   

Abstract

The enzymatic glucuronidation of 3'-azido-3'-deoxythymidine (AZT) catalyzed by human liver microsomal UDP-glucuronosyltransferase (EC 2.4.1.17, UDPGT) was inhibited by a number of nucleoside analogs. The inhibitory potency of these nucleoside analogs correlated with their hydrophobicity (r2 = 0.90, N = 13). Since similar results were obtained with solubilized UDPGT (r2 = 0.87, N = 7), the affinity of the nucleosides for UDPGT was probably being assessed rather than the ability of the compounds to access the membrane-bound enzyme. Three homologous inhibitors, 3'-azido-2',3'-dideoxyuridine (AzddU), 5-ethyl-AzddU, and 5-propyl-AzddU, were also studied as substrates of UDPGT. The substrate efficiency (Vmax/Km) of these three compounds and AZT also correlated with their hydrophobicity (r2 = 0.94). Sixteen drugs that are structurally unrelated to nucleosides also inhibited the glucuronidation of AZT. The mechanism of inhibition was competitive for seven compounds tested. Ki values were estimated from Dixon plots for nine other less soluble inhibitors; their mechanism of inhibition was assumed to be competitive. Since the peak physiological drug concentrations of the tested inhibitors are considerably less than their Ki values, none of these compounds are expected to strongly inhibit AZT glucuronidation in humans. However, the rank order of these drugs with respect to their inhibitory potential is probenecid greater than chrloramphenicol greater than naproxen greater than phenylbutazone much greater than other drugs tested.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1907149     DOI: 10.1016/0006-2952(91)90319-z

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  11 in total

1.  Absence of effect of trimethoprim-sulfamethoxazole on pharmacokinetics of zidovudine in patients infected with human immunodeficiency virus.

Authors:  E Cañas; J Pachon; F Garcia-Pesquera; J R Castillo; P Viciana; J M Cisneros; M E Jimenez-Mejias
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

2.  Extrahepatic metabolism of zidovudine.

Authors:  J L Howe; D J Back; J Colbert
Journal:  Br J Clin Pharmacol       Date:  1992-02       Impact factor: 4.335

3.  Weight related differences in the pharmacokinetics of abacavir in HIV-infected patients.

Authors:  V Jullien; J-M Tréluyer; H Chappuy; J Dimet; E Rey; N Dupin; D Salmon; G Pons; S Urien
Journal:  Br J Clin Pharmacol       Date:  2005-02       Impact factor: 4.335

4.  Comparative effects of antifungal agents on zidovudine glucuronidation by human liver microsomes.

Authors:  E Sampol; B Lacarelle; J F Rajaonarison; J Catalin; A Durand
Journal:  Br J Clin Pharmacol       Date:  1995-07       Impact factor: 4.335

5.  Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine.

Authors:  L L von Moltke; D J Greenblatt; M M Cotreau-Bibbo; J S Harmatz; R I Shader
Journal:  Br J Clin Pharmacol       Date:  1994-07       Impact factor: 4.335

6.  Glucuronidation of the antiretroviral drug efavirenz by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudine.

Authors:  Anne-Sophie Bélanger; Patrick Caron; Mario Harvey; Peter A Zimmerman; Rajeev K Mehlotra; Chantal Guillemette
Journal:  Drug Metab Dispos       Date:  2009-06-01       Impact factor: 3.922

7.  Pharmacokinetics and bioavailability of zidovudine and its glucuronidated metabolite in patients with human immunodeficiency virus infection and hepatic disease (AIDS Clinical Trials Group protocol 062).

Authors:  K H Moore; R H Raasch; K L Brouwer; K Opheim; S H Cheeseman; E Eyster; S M Lemon; C M van der Horst
Journal:  Antimicrob Agents Chemother       Date:  1995-12       Impact factor: 5.191

8.  Zidovudine pharmacokinetics in zidovudine-induced bone marrow toxicity.

Authors:  M Barry; J L Howe; D J Back; A M Swart; A M Breckenridge; I V Weller; N Beeching; F Nye
Journal:  Br J Clin Pharmacol       Date:  1994-01       Impact factor: 4.335

9.  Glucuronidation of 3'-azido-3'-deoxythymidine (zidovudine) by human liver microsomes: relevance to clinical pharmacokinetic interactions with atovaquone, fluconazole, methadone, and valproic acid.

Authors:  C B Trapnell; R W Klecker; C Jamis-Dow; J M Collins
Journal:  Antimicrob Agents Chemother       Date:  1998-07       Impact factor: 5.191

10.  5-Chloro-2',3'-dideoxy-3'-fluorouridine (935U83), a selective anti-human immunodeficiency virus agent with an improved metabolic and toxicological profile.

Authors:  S M Daluge; D J Purifoy; P M Savina; M H St Clair; N R Parry; I K Dev; P Novak; K M Ayers; J E Reardon; G B Roberts
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.